Puneet Sud, MD
Internal Medicine · Providence, RINPI 1598762346
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 253 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 253 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Lilly USA, LLC$659
- Pfizer$654
- AbbVie$529
- AstraZeneca$213
- Johnson & Johnson$171
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,994100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 67 | $1,153 |
| Lilly USA, LLC | 35 | $659 |
| Pfizer | 31 | $654 |
| AbbVie | 24 | $529 |
| AstraZeneca | 6 | $213 |
| Johnson & Johnson | 4 | $171 |
| Novartis | 5 | $170 |
| Abbott | 9 | $165 |
| Mylan Specialty L.p. | 6 | $130 |
| Orexo US, Inc. | 9 | $128 |
| Nestle Healthcare Nutrition Inc. | 5 | $121 |
| Sanofi-aventis U.S. LLC | 7 | $111 |
| Kowa Pharmaceuticals America, Inc. | 6 | $91 |
| Exact Sciences | 4 | $82 |
| GSK | 4 | $71 |
| Sumitomo Pharma America, Inc. | 3 | $62 |
| E.r. Squibb & Sons, L.L.C. | 4 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Gilead | 2 | $44 |
| Phathom Pharmaceuticals, Inc. | 2 | $42 |
| Amgen | 2 | $42 |
| Dexcom, Inc. | 2 | $35 |
| Boehringer Ingelheim | 2 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $27 |
| Corcept Therapeutics | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Braeburn Inc. | 1 | $19 |
| Evoke Pharma, Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| MDD US Operations, LLC | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$118
- LEQVIO$106
- FARXIGA$106
- PREVNAR 20$100
How this compares
$4,994 in reported general payments places this provider in the 90th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 102 | $70,065 |
| PercocetOxycodone Hcl/Acetaminophen | 13 | $59,259 |
| JardianceEmpagliflozin | 51 | $50,695 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 46 | $29,646 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $28,427 |
| MounjaroTirzepatide | 24 | $24,359 |
| TrulicityDulaglutide | 28 | $24,191 |
| OzempicSemaglutide | 26 | $24,126 |
| XareltoRivaroxaban | 20 | $19,904 |
| JanuviaSitagliptin Phosphate | 11 | $17,660 |
| RybelsusSemaglutide | 12 | $16,462 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 91 | $15,279 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $10,268 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,970 |
| Atorvastatin Calcium | 580 | $6,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $654 | $70,065102 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $34 | $57,66465 claims |
| Lilly USA, LLCMounjaro, Trulicity | $659 | $48,55052 claims |
| Novo NordiskOzempic, Rybelsus | $1,153 | $40,58938 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $71 | $32,98756 claims |
| Johnson & JohnsonXarelto | $171 | $19,90420 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $111 | $10,26813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Providence
- Katarzyna Gilek-SeibertProvidence$131K
- Randall InghamProvidence$100K
- Richard RuggieriProvidence$30K
- Gerry OvideProvidence$29K
- Brian McCauleyProvidence$20K
- Meghan NahassProvidence$19K
- William LangProvidence$15K
- Abdelmoniem MoustafaProvidence$13K
- Khushal ChoudharyProvidence$10K
- Kenneth ChenProvidence$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.